Type 2 diabetes
Conditions
Interventions
Tirzepatide group:The initial dose is 2.5 mg once weekly. After 4 weeks, the dose can be increased to 5 mg based on tolerability and efficacy, followed by further increases every 4 weeks to 7.5 mg, 10
Semaglutide group:The initial dose is 0.25 mg once weekly. After 4 weeks, the dose can be increased to 0.5 mg based on tolerability and efficacy, followed by further increases every 4 weeks to 0.75 mg
Sponsors
General Hospital of Central Theater Command
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Confirmed T2DM patients (meeting the diagnostic criteria of the 2023 WHO), with a disease course of T2DM = 6 months, who have never used any hypoglycemic drugs (including oral hypoglycemic agents, GLP-1RA, and insulin) and have only received lifestyle intervention; 2) Age 40-70 years, gender unrestricted; 3) 6.5% = 10% to rule out structural vascular disease; 5) Blood pressure < 140/90 mmHg; LDL-C <= 2.6 mmol·L?¹, and have never used antihypertensive or lipid-lowering drugs; 6) Agree to participate in the clinical trial and be able to follow up in a timely manner as required by the study.
Exclusion criteria
Exclusion criteria: 1) A history of type 1 diabetes, acute diabetic complications, unconscious hypoglycemia, or pancreatitis; 2) Non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, or diabetic macular edema requiring urgent treatment; 3) Allergy or contraindication to tirzepatide; 4) Gastroparesis; 5) Critical illness (such as cancer, severe infection, active tumor, autoimmune disease, etc.); 6) Previous occurrence of severe cardiovascular events (such as myocardial infarction, stroke, vascular reconstruction surgery or major surgical history); 7) Severe liver or kidney dysfunction (ALT/AST >= 3 times the upper limit of normal or eGF < 30 mL/min/1.73m^2); 8) Pregnant or lactating women; 9) Mental illness or inability to cooperate with follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow-mediated diastolic function of the brachial artery, FMD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Microvascular reactivity;Metabolic indicators: HbA1c, fasting blood glucose, adiponectin, insulin resistance index (HOMA-IR), Body weight and waist circumference.;Markers of inflammation; | — |
Countries
China
Contacts
Public ContactXiang Lin
General Hospital of Central Theater Command
Outcome results
None listed